Research map: IFN-related gene expression defines disease activity, organ involvement and treatment response in JDM

Back to the article

Papers in this map

  1. Fitting Linear Mixed-Effects Models Using lme4 · Douglas M. Bates · 2015 · 89318 citations · Cited by this paper
  2. Examining the role of dipeptidyl peptidase IV (DPPIV) in psoriatic disease · 2026 · Related
  3. Polymyositis and Dermatomyositis · Anthony Bohan · 1975 · 5134 citations · Cited by this paper
  4. Association of Th2-like inflammation with a Tfh/Tph–germinal center immune programs in submandibular gland lesions of IgG4-related disease · 2026 · Related
  5. Polymyositis and Dermatomyositis · Anthony Bohan · 1975 · 2470 citations · Cited by this paper
  6. Characterizing arthritis subtypes in lupus: prevalence, clinical features and role of type I interferon signatures · 2026 · Related
  7. Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package lcmm · Cécile Proust-Lima · 2017 · 1063 citations · Cited by this paper
  8. Patient global assessment in rheumatoid arthritis: general health and disease activity are not interchangeable · 2026 · Related
  9. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial · Nicolino Ruperto · 2015 · 239 citations · Cited by this paper
  10. Mechanisms, clinical manifestations and management of cardiovascular diseases in ANCA-associated vasculitis · 2026 · Related
  11. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis · Dragana Lazarević · 2012 · 172 citations · Cited by this paper
  12. Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK · 2026 · Related
  13. Juvenile dermatomyositis: A clinical and immunologic study · Lauren M. Pachman · 1980 · 139 citations · Cited by this paper
  14. Plasma metabolomics and incident major adverse cardiovascular events in patients with rheumatoid arthritis · 2026 · Related
  15. Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features · Gian Marco Moneta · 2018 · 101 citations · Cited by this paper
  16. Standardization of minor salivary gland biopsy interpretation in Sjögren’s disease using the 2017 EULAR recommendations: a monocentric study · 2026 · Related
  17. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course · Ann M. Reed · 2012 · 100 citations · Cited by this paper
  18. Cardiac involvement in Behçet’s syndrome: findings from a clinically driven cardiological evaluation · 2026 · Related
  19. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis · Charalampia Papadopoulou · 2019 · 97 citations · Cited by this paper
  20. Updates in juvenile dermatomyositis: pathogenesis and therapy · 2025 · Related
  21. Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation · Judith Wienke · 2019 · 96 citations · Cited by this paper
  22. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative · Rohit Aggarwal · 2017 · 94 citations · Cited by this paper
  23. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study · Tom Le Voyer · 2021 · 87 citations · Cited by this paper
  24. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies · Cristina Cappelletti · 2011 · 83 citations · Cited by this paper
  25. Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis · Ebun Omoyinmi · 2017 · 82 citations · Cited by this paper
  26. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care · Charalampia Papadopoulou · 2023 · 82 citations · Cited by this paper
  27. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review · Julie J. Paik · 2022 · 73 citations · Cited by this paper
  28. Juvenile dermatomyositis: Latest advances · Qiong Wu · 2017 · 68 citations · Cited by this paper
  29. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies · Hanna Kim · 2020 · 67 citations · Cited by this paper
  30. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response · Butsabong Lerkvaleekul · 2021 · 62 citations · Cited by this paper
  31. Endothelial injury and repair in systemic vasculitis of the young · L. A. Clarke · 2010 · 59 citations · Cited by this paper
  32. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review · Zhongxun Yu · 2020 · 55 citations · Cited by this paper
  33. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy · Hanna Kim · 2021 · 52 citations · Cited by this paper
  34. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis · Mengya Chen · 2018 · 49 citations · Cited by this paper
  35. Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis · Meredyth Grace Llewellyn Wilkinson · 2022 · 49 citations · Cited by this paper
  36. Advances in the classification and management of idiopathic inflammatory myopathies · Joost Raaphorst · 2025 · 39 citations · Cited by this paper
  37. Increased IL‐18 Production by Dendritic Cells in Active Inflammatory Myopathies · Marco Tucci · 2007 · 34 citations · Cited by this paper
  38. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis · Erdal Sağ · 2020 · 30 citations · Cited by this paper
  39. Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis · Silvia Rosina · 2018 · 27 citations · Cited by this paper

Source: OpenAlex (CC0)